1012 GMT - While Philips expects organic sales growth to improve in 2026, doubling of the growth rate is unlikely, Chief Executive Roy Jakobs told Citi analysts at the Global Healthcare Conference. Philips saw growth improve 1% in 2024 and guides for around 2% in 2025, Citi analysts say in a research note. The Dutch health-technology company's call of caution means that organic sales growth should be more than 2% but less than 4%, compared with company-compiled consensus of 4.5%, Citi says. Jakobs said the company still expects margins to expand in 2026, but tariff impacts will almost double year-on-year, Citi notes. Nevertheless, Citi sees Philips on track, the analysts say. Shares trade 7.4% lower at 22.27 euros. (nina.kienle@wsj.com)
(END) Dow Jones Newswires
December 04, 2025 05:16 ET (10:16 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Comments